Service of Neurology and Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Hospital Clínic, University of Barcelona, Barcelona, Spain.
Semin Neurol. 2010 Jul;30(3):287-95. doi: 10.1055/s-0030-1255218. Epub 2010 Jun 24.
Hematopoietic cell transplantation (HCT) involves the intravenous infusion of hematopoietic progenitor cells from an HLA-matched donor (allogeneic) or from the patient (autologous). Prior to HCT, the recipient is prepared (conditioning) with high-dose chemotherapy or radiotherapy (or both) to destroy defective bone marrow or residual cancer cells. After allogeneic HCT, there is the need for chronic immunosuppression to prevent graft rejection and graft-versus-host disease (GVHD). The frequency and type of neurologic complications depends on the type of HCT, the underlying disease, and the case ascertainment. In this review, the neurologic complications are presented according to the stage of HCT that they are most likely to occur: (1) conditioning-drug-related encephalopathies and seizures or complications secondary to medical procedures; (2) bone marrow depletion-metabolic and drug-related encephalopathies and seizures, septic cerebral infarctions, and hemorrhages; (3) chronic immunosuppression-infections by viruses and opportunistic organisms; and (4) late events-central nervous system (CNS) relapses of the original disease, neurologic complications of GVHD, and second neoplasms.
造血细胞移植(HCT)涉及从 HLA 匹配的供体(同种异体)或患者自身(自体)静脉输注造血祖细胞。在 HCT 之前,受者接受高剂量化疗或放疗(或两者)预处理(调理),以破坏有缺陷的骨髓或残留癌细胞。在同种异体 HCT 后,需要慢性免疫抑制来预防移植物排斥和移植物抗宿主病(GVHD)。神经并发症的频率和类型取决于 HCT 的类型、基础疾病和病例确定。在本综述中,根据 HCT 最可能发生的阶段呈现神经并发症:(1)调理药物相关脑病和癫痫发作或与医疗程序相关的并发症;(2)骨髓耗竭-代谢和药物相关脑病和癫痫发作、脓毒性脑梗死和出血;(3)慢性免疫抑制-病毒和机会性生物体感染;和(4)晚期事件-原始疾病的中枢神经系统(CNS)复发、GVHD 的神经并发症和第二肿瘤。